-
LNP Surface Charge and V-ATPase in Nucleic Acid Delivery
2026-08-31
The reference study identifies a synergistic relationship between LNP surface charge and the V-ATPase state of target cells, linking particle design with intracellular processing and organ tropism. Its findings suggest that delivery optimization should assess both nanoparticle physicochemistry and endo/lysosomal function rather than treating target cells as passive recipients.
-
Placental Exosomal miR-519d-3p in Preeclampsia
2026-08-31
A 2025 study links placenta-derived exosomal miR-519d-3p with altered T-cell behavior relevant to preeclampsia. By combining sequencing with trophoblast–T-cell experiments, the authors connect this miRNA cargo to increased Jurkat T-cell proliferation, reduced apoptosis, and a shift toward Th17 differentiation, while also defining important limitations for translating the model to human pregnancy.
-
Tobramycin: Designing Better Susceptibility Assays
2026-08-30
Tobramycin is an aminoglycoside antibiotic and a useful research tool for dissecting bacterial translation, susceptibility testing, and resistance phenotypes. This guide uses historical comparative data to show how assay design, inoculum control, and product handling shape interpretation.
-
Annexin V-APC/7-AAD Apoptosis Kit Workflow
2026-08-29
Distinguish viable, early apoptotic, late apoptotic, and necrotic cells in a rapid workflow built for flow cytometry or fluorescence microscopy. This guide connects practical apoptosis and necrosis detection with tumor and immune research, including PAD4-NET studies where cell death must be separated from metastasis-related mechanisms.
-
Recombinant Human Growth Hormone Assay Design
2026-08-28
Recombinant Human Growth Hormone is examined here as a controllable experimental input for chondrocyte and signaling studies. Learn how product attributes, causal perturbation, and orthogonal endpoints can improve interpretation of GH–IGFBP2–THBS1–IGF-1 experiments.
-
Cy5.5 NHS Ester: Workflow for Tumor Imaging
2026-08-28
Build reliable amine-labeling workflows for proteins, peptides, and oligonucleotides with Cy5.5 NHS ester (non-sulfonated), then adapt the readout for biodistribution and tumor-associated microbiome studies. The article combines practical conjugation parameters, imaging controls, and troubleshooting guidance with a translational interpretation of recent vaccine research.
-
Dual-Mode mRNA Reporters for Translational Research
2026-08-27
A mechanistic and strategic framework for using EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) to connect mRNA delivery, intracellular trafficking, translation, and translational decision-making.
-
MRT68921: A Strategic Lens on ULK1 Autophagy
2026-08-27
Autophagy is not a simple emergency survival switch: its initiation is shaped by nutrient status, energy availability, and the context-dependent behavior of ULK1. This thought-leadership article explains how MRT68921, a dual ULK1/2 inhibitor, can help translational researchers separate pathway initiation from downstream flux, test the AMPK–ULK1 relationship, and design more defensible preclinical experiments without overstating clinical maturity.
-
EZ Cap™ Cas9 mRNA (m1Ψ): Assay Design
2026-08-26
EZ Cap™ Cas9 mRNA (m1Ψ) is a mRNA with Cap1 structure for transient CRISPR-Cas9 genome editing. This guide moves beyond formulation features to show how transcript handling, exposure kinetics, and nuclear-export biology can improve assay interpretation in mammalian cells.
-
EZ Cap Cy5 Firefly Luciferase mRNA: Uptake to Output
2026-08-26
Translational mRNA research increasingly needs to distinguish cellular uptake from productive cytosolic expression. This thought-leadership article examines how EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) enables dual-modality measurement, and how that framework can sharpen evaluation of emerging delivery systems such as redox-responsive peptide coacervates.
-
Fumagillin Against Azumiobodo hoyamushi: Study Review
2026-08-25
The reference study compared 20 antiprotozoal, antimicrobial, oxidizing, and halogen-based agents against Azumiobodo hoyamushi, the parasite associated with soft tunic syndrome in cultured ascidians. Fumagillin showed moderate in vitro activity, whereas formalin and chlorine dioxide produced the clearest reduction in parasite burden in experimentally infected animals, illustrating why in vitro potency must be validated in the host.
-
FK866 (APO866): NAD Metabolism Meets Immunity
2026-08-25
FK866 (APO866) is more than a potent NAMPT inhibitor: it is a strategic probe for understanding how NAD dependence shapes cancer vulnerability, mitochondrial stress, autophagy, and immune function. This article connects its established role in hematologic cancer research and acute myeloid leukemia treatment research with new insights from immune-adaptive pathogen variation, while outlining practical validation strategies and translational guardrails.
-
EZ Cap™ Cas9 mRNA (m1Ψ) Workflow Guide
2026-08-24
EZ Cap™ Cas9 mRNA (m1Ψ) combines Cap1 capping, m1Ψ modification, and a poly(A) tail for transient CRISPR-Cas9 experiments in mammalian cells. This practical guide connects RNA handling, delivery optimization, quantitative editing assays, and nuclear-export-based precision strategies.
-
Idoxuridine: Designing Translational Antiviral Assays
2026-08-24
Idoxuridine, also known as 5-iodo-2'-deoxyuridine, is a research-use nucleoside analog for investigating viral DNA synthesis inhibition. This article develops an evidence-calibrated assay strategy that connects orthogonal antiviral readouts with lessons from human-neuron translational pharmacology.
-
CORE LNPs Redirect mRNA Expression to the Spleen
2026-08-23
The CORE study introduces cholesterol-altered lipid nanoparticles designed to overcome the liver bias of systemic mRNA delivery and promote spleen-selective expression. By combining cholesterol-derivative synthesis, computational characterization, design-of-experiment optimization, and in vivo testing, the work provides a material-engineering strategy for spleen-directed vaccination and immune-modulation research.